Pharmacotherapy in smoking cessation: Corticotropin Releasing Factor receptors as emerging intervention targets. (June 2017)

• Record Type: Journal Article
• Authors: Sotiriou, Ioannis; Chalkiadaki, Kleanthi; Nikolaidis, Christos; Sidiropoulou, Kyriaki; Chatzaki, Ekaterini
• Is Part Of: Neuropeptides. Volume 63(2017)
• Page Start: 49
• Page End: 57
• Publication Date: 2017-06
• Subjects: Corticotropin Releasing Factor -- Receptor -- Nicotine -- Smoking cessation -- Pharmacotherapy; Neuropeptides -- Periodicals; Neuropeptides; Neuropeptides -- Périodiques; Neuropeptides; Electronic journals; Periodicals; 572.65
• DOI: 10.1016/j.npep.2017.02.082
• Languages: English
• ISSNs: 0143-4179

Abstract

Abstract: Smoking represents perhaps the single most important health risk factor and a global contributor to mortality that can unquestionably be prevented. Smoking is responsible for many diseases, including various types of cancer, chronic obstructive pulmonary disease, coronary heart disease, peripheral vascular disease and peptic ulcer, while it adversely affects fetal formation and development. Since smoking habit duration is a critical factor for mortality, the goal of treatment should be its timely cessation and relapse prevention. Drug intervention therapy is an important ally in smoking cessation. Significant positive steps have been achieved in the last few years in the development of supportive compounds. In the present review, we analyze reports studying the role of Corticotropin Releasing Factor (CRF), the principle neuroendocrine mediator of the stress response and its two receptors (CRF1 and CRF2) in the withdrawal phase as well as in the abstinence from nicotine use. Although still in pre-clinical evaluation, therapeutic implications of these data were investigated in order to highlight potential pharmaceutical interventions. Highlights: Pharmacotherapy supportive to smoking cessation holds some proven potential. CRF is involved in stress-induced nicotine seeking behavior. Pre-clinical studies show favorable actions of CRF antagonists. The nicotine withdrawal and abstinence phase could be supported.